This is a prospective, multicentre, investigator-initiated, randomized clinical trial
clinical trial investigating the impact of beta-blockers administration among patients
undergoing TAVI for severe aortic valve stenosis. Adults already receiving beta-blockers be
assigned randomly in 1:1 ratio to either continue or withdraw the beta-blockers medication at
least 72 hours before and at least 7 days after TAVI. The primary endpoint is permanent
pacemaker implantation rates in 7 days after the procedure. Secondary endpoints include
death, cardiogenic shock and arrhythmias/conduction abmormalities with time frame 12 months.